.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
McKesson
UBS
Dow
US Department of Justice
Farmers Insurance
Chubb
Healthtrust
Merck
Chinese Patent Office

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075215

« Back to Dashboard
NDA 075215 describes LABETALOL HYDROCHLORIDE, which is a drug marketed by West-ward Pharms Int, Par Form, Sandoz, Innogenix, Apothecon, Akorn Inc, Watson Labs, Sagent Agila Llc, Hospira, Zydus Pharms Usa Inc, Baxter Hlthcare Corp, Ivax Sub Teva Pharms, Teva, and Gland Pharma Ltd, and is included in eighteen NDAs. It is available from twenty-nine suppliers. Additional details are available on the LABETALOL HYDROCHLORIDE profile page.

The generic ingredient in LABETALOL HYDROCHLORIDE is labetalol hydrochloride. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.

Summary for 075215

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 075215

Mechanism of ActionAdrenergic beta-Antagonists

Suppliers and Packaging for NDA: 075215

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LABETALOL HYDROCHLORIDE
labetalol hydrochloride
TABLET;ORAL 075215 ANDA Sun Pharmaceutical Industries, Inc. 57664-650 57664-650-88 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (57664-650-88)
LABETALOL HYDROCHLORIDE
labetalol hydrochloride
TABLET;ORAL 075215 ANDA Sun Pharmaceutical Industries, Inc. 57664-651 57664-651-88 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (57664-651-88)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Jul 29, 1999TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength200MG
Approval Date:Jul 29, 1999TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Jul 29, 1999TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Dow
Colorcon
Moodys
Chubb
Argus Health
Cipla
Harvard Business School
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot